177Lu-DOTATATE and 177Lu-prostate-specific membrane antigen therapy in a patient with advanced metastatic radioiodine-refractory differentiated thyroid cancer after failure of tyrosine kinase inhibitors treatment
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
177Lu-DOTATATE and 177Lu-prostate-specific membrane antigen therapy in a patient with advanced metastatic radioiodine-refractory differentiated thyroid cancer after failure of tyrosine kinase inhibitors treatment ; volume:18 ; number:04 ; year:2019 ; pages:406-408
World Journal of Nuclear Medicine ; 18, Heft 04 (2019), 406-408
- Contributor
- DOI
-
10.4103/wjnm.WJNM_112_18
- URN
-
urn:nbn:de:101:1-2022060911304422936686
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:37 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Assadi, Majid
- Ahmadzadehfar, Hojjat
Other Objects (12)
90Y/177Lu-DOTATATE therapy: survival of the fittest?
Tissue dose estimation after extravasation of 177Lu-DOTATATE
Concomitant 177Lu-DOTATATE and capecitabine therapy in malignant paragangliomas
p53 stabilisation potentiates [177Lu]Lu-DOTATATE treatment in neuroblastoma xenografts
Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry
Dosimetric implications of kidney anatomical volume changes in 177Lu-DOTATATE therapy
Practical kidney dosimetry in peptide receptor radionuclide therapy using [177Lu]Lu-DOTATOC and [177Lu]Lu-DOTATATE with focus on uncertainty estimates
Survival predictors of 177Lu-Dotatate peptide receptor radionuclide therapy (PRRT) in patients with progressive well-differentiated neuroendocrine tumors (NETS)
Lymphopenia during 177Lu-DOTATATE therapy leading to recurrence of tuberculosis: a case report
Accuracy and precision assessment for activity quantification in individualized dosimetry of 177Lu-DOTATATE therapy
Dose mapping after endoradiotherapy with 177Lu-DOTATATE/DOTATOC by a single measurement after 4 days
Radiation precautions for inpatient and outpatient 177Lu-DOTATATE peptide receptor radionuclide therapy of neuroendocrine tumours
90Y/177Lu-DOTATATE therapy: survival of the fittest?
Tissue dose estimation after extravasation of 177Lu-DOTATATE
Concomitant 177Lu-DOTATATE and capecitabine therapy in malignant paragangliomas
p53 stabilisation potentiates [177Lu]Lu-DOTATATE treatment in neuroblastoma xenografts
Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry
Dosimetric implications of kidney anatomical volume changes in 177Lu-DOTATATE therapy
Practical kidney dosimetry in peptide receptor radionuclide therapy using [177Lu]Lu-DOTATOC and [177Lu]Lu-DOTATATE with focus on uncertainty estimates
Survival predictors of 177Lu-Dotatate peptide receptor radionuclide therapy (PRRT) in patients with progressive well-differentiated neuroendocrine tumors (NETS)
Lymphopenia during 177Lu-DOTATATE therapy leading to recurrence of tuberculosis: a case report
Accuracy and precision assessment for activity quantification in individualized dosimetry of 177Lu-DOTATATE therapy
Dose mapping after endoradiotherapy with 177Lu-DOTATATE/DOTATOC by a single measurement after 4 days
Radiation precautions for inpatient and outpatient 177Lu-DOTATATE peptide receptor radionuclide therapy of neuroendocrine tumours
90Y/177Lu-DOTATATE therapy: survival of the fittest?
Tissue dose estimation after extravasation of 177Lu-DOTATATE
Concomitant 177Lu-DOTATATE and capecitabine therapy in malignant paragangliomas
p53 stabilisation potentiates [177Lu]Lu-DOTATATE treatment in neuroblastoma xenografts
Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry
Dosimetric implications of kidney anatomical volume changes in 177Lu-DOTATATE therapy
Practical kidney dosimetry in peptide receptor radionuclide therapy using [177Lu]Lu-DOTATOC and [177Lu]Lu-DOTATATE with focus on uncertainty estimates
Survival predictors of 177Lu-Dotatate peptide receptor radionuclide therapy (PRRT) in patients with progressive well-differentiated neuroendocrine tumors (NETS)
Lymphopenia during 177Lu-DOTATATE therapy leading to recurrence of tuberculosis: a case report
Accuracy and precision assessment for activity quantification in individualized dosimetry of 177Lu-DOTATATE therapy
Dose mapping after endoradiotherapy with 177Lu-DOTATATE/DOTATOC by a single measurement after 4 days